Cromos Pharma, where the patients are

Celgene

Ian Read becomes PhRMA board chairman; Ken Frazier, George Scangos on board

Friday, April 18, 2014 10:37 AM

Ian C. Read, chairman and CEO of Pfizer, was elected chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA). Read succeeds Robert J. Hugin, chairman and CEO of Celgene, as PhRMA's chairman. Also elected were Kenneth C. Frazier, chairman, president and CEO of Merck, as chairman-elect of the PhRMA board of directors, and George A. Scangos, Ph.D., CEO of Biogen Idec, as board treasurer.

More... »

CRF Health eCOA webinar series

CEO Roundtable on Cancer launches data-sharing initiative to accelerate drug development

Thursday, April 10, 2014 01:03 PM

The CEO Roundtable on Cancer has launched Project Data Sphere, a new online oncology data-sharing platform using de-identified cancer patient information with the goal of accelerating drug discovery—by developing more efficient clinical trial protocols, epidemiological studies and, ultimately, new cancer therapies. 

More... »


FDA approves Otezla to treat psoriatic arthritis

Friday, March 28, 2014 12:50 PM

The FDA has approved Otezla (apremilast) to treat adults with active psoriatic arthritis (PsA).

More... »

Orphan drug market expected to grow through 2018

Monday, March 24, 2014 02:51 PM

The returns on investment from orphan drugs are expected to help pharma companies overcome the impact of revenue loss due to expiry of patents of blockbuster drugs, according to ReportsnReports.com.

More... »

Agios enrolls first patient in phase I study of AG-120

Friday, March 21, 2014 09:49 AM

Agios Pharmaceuticals, a company focused on discovering and developing novel drugs to treat cancer and inborn errors of metabolism (IEMs), has announced that the first patient has been dosed in a phase I study of AG-120 in patients with advanced hematologic malignancies with an isocitrate dehydrogenase-1 (IDH1) mutation. AG-120 is an orally available, selective, potent inhibitor of the mutated IDH1 protein, making it the first targeted therapeutic candidate to treat patients with cancers that harbor the IDH1 mutation.

More... »

Abide Therapeutics, Celgene collaborate on immune disorders

Monday, March 3, 2014 12:50 PM

Abide Therapeutics has entered into a strategic collaboration with Celgeneto discover and develop new drugs in inflammation and immunology. Abide has pioneered innovative technologies to selectively target serine hydrolases, one of the largest enzyme families involved in regulating human physiology.

More... »

Report: Absence of 2014 blockbuster drug launches puts R&D productivity at risk

Monday, February 10, 2014 09:54 AM

The past two years have brought a surge of R&D productivity, driving investor confidence and increasing market performance, but 2014 looks to tell a different tale according to a new report from EP Vantage, a source of life science market intelligence and analysis.

More... »

Perrigo names board of directors

Friday, December 20, 2013 02:11 PM

Dublin, Ireland-based Perrigo has announced the appointment of its board of directors, effective until Perrigo’s annual general meeting scheduled for November 2014. The appointment of the Perrigo board follows the completion of Perrigo’s acquisition of Elan in a cash and stock transaction valued at approximately $8.6 billion. The transaction will create a global healthcare company with a growth profile.

More... »

OncoMed, Celgene collaborate

Wednesday, December 4, 2013 12:55 PM

OncoMed Pharmaceuticals and Celgene have inked an agreement to jointly develop and commercialize up to six anti-cancer stem cell (CSC) product candidates from OncoMed's biologics pipeline, including demcizumab.

More... »

Alliqua, Celgene ink licensing agreement

Wednesday, November 20, 2013 12:53 PM

Alliqua, a biopharmaceutical company focused on the development, manufacturing and distribution of proprietary transdermal wound care and drug delivery technologies, entered into a licensing agreement with Celgene Cellular Therapeutics (CCT), a subsidiary of Celgene, whereby Alliqua received the right to develop and market the advanced wound care products Biovance and Extracellular Matrix (ECM).

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

April 14

Proposal calls for back-to-back trials to measure efficacy and effectiveness prior to FDA approval

Study: Minority populations under-represented in cancer trials, but have higher rates of incidence

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

Make way for mobile health in clinical trials
Despite patient retention, data quality benefits, regulatory hurdles persist

Global clinical trial laboratories decentralize
Regional labs reducing complexity, delivering cost and time savings

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Strategic alliances hit bumps in the road
Mixed relationship performance driving new approaches

Tapping community hospitals for clinical trial volunteers
New study finds high potential but infrastructure, resources are lacking

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs